Thioredoxin in cancer--role of histone deacetylase inhibitors

Semin Cancer Biol. 2006 Dec;16(6):436-43. doi: 10.1016/j.semcancer.2006.09.005. Epub 2006 Sep 26.

Abstract

Increased levels of thioredoxin (Trx) occur in a number of human cancers, which may contribute to the resistance of cancers to therapy by scavenging reactive oxygen species (ROS) which are generated by various anti-cancer agents. Many human cancers have low levels of thioredoxin-binding protein (TBP-2). TBP-2 binds to Trx and blocks its reducing activity. Histone deacetylase inhibitors (HDACi) up-regulate TBP-2 in various transformed cells, associated with a decrease in Trx levels. Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Enzyme Inhibitors / pharmacology*
  • Histone Deacetylase Inhibitors*
  • Humans
  • Neoplasms / metabolism*
  • Thioredoxins / metabolism*

Substances

  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Thioredoxins